Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 4Neoplasms 3Myelodysplastic Syndromes 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hodgkin Disease 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 282Rituximab 260Etoposide 161Filgrastim 155Vincristine 145Doxorubicin 134Prednisone 117Cytarabine 108Radiotherapy 102Peripheral Blood Stem Cell Transplantation 90Methotrexate 90fludarabine phosphate 87Melphalan 78Busulfan 71Dexamethasone 59Granulocyte Colony-Stimulating Factor 56Carmustine 53fludarabine 51Bortezomib 46Tacrolimus 44Mycophenolic Acid 41Antilymphocyte Serum 41Ifosfamide 40Leucovorin 39Gemcitabine 38Whole-Body Irradiation 36Cyclosporine 35Bendamustine Hydrochloride 34sargramostim 33Methylprednisolone 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma × ALT-803 × Clear all
NCT01885897 2020-08-12

IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT

Masonic Cancer Center, University of Minnesota

Phase 1/2 Completed
33 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡